Hey Mozz - Amgen just announced a takeover of a phase 3 ready bio on the oncology field. One of the reasons stated for the takeover was to maintain a lead in Oncology field.
Upon further reading, Amgen's blockbuster drug is Enbrel - have you written about Enbrel before? it's a RA drug and I just wonder if an OA drug may just fit the portfolio of a company like Amgen...perhaps compliments their RA offering. Regardless, Enbrel just might provide some insight to the pathway Zilosul could potentially take one day - in terms of cost to patient and revenues it could generate.
Hey Mozz - Amgen just announced a takeover of a phase 3 ready...
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
25.0¢ |
Change
-0.005(1.96%) |
Mkt cap ! $87.44M | |||
| Open | High | Low | Value | Volume |
| 25.0¢ | 25.5¢ | 25.0¢ | $13.08K | 51.83K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 133489 | 25.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 26.0¢ | 25012 | 2 |
View Market Depth
| Last trade - 16.10pm 02/08/2024 (20 minute delay) ? |
| PAR (ASX) Chart |